RxDoctor Payments Data

Reuven Bromberg, MD

Rheumatology · Miami, FLNPI 1487856571

Payments from drug & device makers

$78,099in general payments, 2019–2025

Across 1,408 payments — averaging $55.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$39K
  • Johnson & Johnson$11K
  • Novartis$10K
  • Amgen$4K
  • AbbVie$4K
  • Pfizer$1K
  • plus $9K from 33 others

What the payments were for

  • Consulting fees$13,58717%
  • Speaking & faculty fees$33,65043%
  • Travel & lodging$2,6503%
  • Food & beverage$27,87836%
  • Education$3350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,099 in reported general payments places this provider in the 75th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$622,152
Medicare patients
75
Services billed
43,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5045$423,293
IlarisCanakinumab/Pf14$328,323
Gamunex-CImmune Globul G/Gly/Iga Avg 4629$244,010
GammakedImmune Globul G/Gly/Iga Avg 4624$226,619
Humira(Cf) PenAdalimumab23$164,376
Xeljanz XrTofacitinib Citrate27$161,867
TavneosAvacopan11$159,938
Actemra ActpenTocilizumab29$144,342
LupkynisVoclosporin13$123,590
RinvoqUpadacitinib12$86,272
Simponi AriaGolimumab12$70,792
RasuvoMethotrexate/Pf64$42,013
Evenity (2 Syringes)Romosozumab-Aqqg12$29,150
ProliaDenosumab15$26,126
FarxigaDapagliflozin Propanediol23$12,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlaris$10,161$328,32314 claims
AmgenTavneos, Evenity (2 Syringes), Prolia$4,336$215,21538 claims
Aurinia Pharma U.S., Inc.Lupkynis$1,330$123,59013 claims
AbbVieRinvoq$4,064$86,27212 claims
Johnson & JohnsonSimponi Aria$10,542$70,79212 claims
Medexus Pharma, Inc.Rasuvo$359$42,01364 claims
AstraZenecaFarxiga$38,533$12,85623 claims
Antares Pharma, Inc.Otrexup$42$12,18112 claims
Fresenius Kabi USA, LLCSodium Chloride$147$12515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →